BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21592158)

  • 1. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain.
    Fortnum H; Lee AJ; Rupnik B; Avery A;
    J Clin Pharm Ther; 2012 Apr; 37(2):161-5. PubMed ID: 21592158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme.
    Krska J; Anderson C; Murphy E; Avery AJ
    Drug Saf; 2011 May; 34(5):429-36. PubMed ID: 21513365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK.
    McLernon DJ; Bond CM; Lee AJ; Watson MC; Hannaford PC; Fortnum H; Krska J; Anderson C; Murphy E; Avery A;
    Pharmacoepidemiol Drug Saf; 2011 May; 20(5):523-31. PubMed ID: 21328634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions.
    Bracchi RC; Tseliou F; Copeland L; Routledge PA; Thomas A; Woods F; Adams A; Walker J; Jadeja M; Atkinson MD; Ashfield-Watt P
    Br J Clin Pharmacol; 2021 Aug; 87(8):3344-3348. PubMed ID: 33386761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do UK dentists deal with adverse drug reaction reporting?
    Yip J; Radford DR; Brown D
    Br Dent J; 2013 Apr; 214(8):E22. PubMed ID: 23619888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Views of British community pharmacists on direct patient reporting of adverse drug reactions (ADRs).
    Krska J
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1130-3. PubMed ID: 22729956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK.
    Thompson A; Randall C; Howard J; Barker C; Bowden D; Mooney P; Munyika A; Smith S; Pirmohamed M
    J Clin Pharm Ther; 2019 Feb; 44(1):78-83. PubMed ID: 30206951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing and further developing age-appropriate information for young people about reporting suspected adverse drug reactions.
    Bioletti L; ; Woodward C; Jadeja M; Hawcutt DB
    Br J Clin Pharmacol; 2024 Mar; 90(3):863-870. PubMed ID: 37990602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low awareness of adverse drug reaction reporting systems: a consumer survey.
    Robertson J; Newby DA
    Med J Aust; 2013 Nov; 199(10):684-6. PubMed ID: 24237099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals.
    McLernon DJ; Bond CM; Hannaford PC; Watson MC; Lee AJ; Hazell L; Avery A;
    Drug Saf; 2010 Sep; 33(9):775-88. PubMed ID: 20701410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting.
    Lorimer S; Cox A; Langford NJ
    J Clin Pharm Ther; 2012 Apr; 37(2):148-52. PubMed ID: 21592157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse effects of neuromuscular blocking agents based on yellow card reporting in the U.K.: are there differences between males and females?
    Light KP; Lovell AT; Butt H; Fauvel NJ; Holdcroft A
    Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):151-60. PubMed ID: 16395661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-medical prescribers and pharmacovigilance: participation, competence and future needs.
    Stewart D; MacLure K; Paudyal V; Hughes C; Courtenay M; McLay J
    Int J Clin Pharm; 2013 Apr; 35(2):268-74. PubMed ID: 23277419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.
    Anderson C; Krska J; Murphy E; Avery A;
    Br J Clin Pharmacol; 2011 Nov; 72(5):806-22. PubMed ID: 21496066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacovigilance Reports Received from Children and Young People, and Development of Information to Aid Future Reporting from this Age Group.
    Bhoombla N; Preston J; Ainsworth J; Bird H; Jadeja M; King C; Hawcutt DB
    Paediatr Drugs; 2020 Jun; 22(3):335-341. PubMed ID: 32253722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
    Jose J; Rao PG
    Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting.
    Green CF; Mottram DR; Rowe PH; Pirmohamed M
    Br J Clin Pharmacol; 2001 Jan; 51(1):81-6. PubMed ID: 11167664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences relating to adverse drug reactions in the community: a cross-sectional survey among patients and the general public in Thailand.
    Patsuree A; Krska J; Jarernsiripornkul N
    Expert Opin Drug Saf; 2016; 15(3):287-95. PubMed ID: 26750422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient and public attitudes towards informed consent models and levels of awareness of Electronic Health Records in the UK.
    Riordan F; Papoutsi C; Reed JE; Marston C; Bell D; Majeed A
    Int J Med Inform; 2015 Apr; 84(4):237-47. PubMed ID: 25649841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.